Vertex Pharmaceuticals Incorporated today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the ...
Third quarter performance driven by strong portfolio royalty revenue growth of 47%2025 full year revenue guidance increased to $225 million - ...
To excel in your CBSE Class 10 Hindi exam, strategic preparation is crucial. For the academic year 2025-26, the CBSE board ...
To excel in your CBSE Class 10 English exam, strategic preparation is crucial. For the academic year 2025-26, the CBSE board ...